Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Feb 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-02-10

Reporting Person: Sullivan Timothy Eugene (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-10	Common Stock	F	858	$47.72	Disposed	34261	Direct

Footnotes

F1: This represents shares withheld for tax on a restricted stock unit release.